Table 3

Comparison of pretransplantation characteristics between MRDneg and MRDpos patients

MRDneg (n = 199)MRDpos (n = 54)P*
Median age at HCT (range), y42.5 (0.6-71.6)47.6 (2.2-72.6)NS
Male gender, n (%)95 (47.7%)36 (66.7%).014
Median WBC at diagnosis, ×103/µL11.6 (0.2-297)5.3 (0.3-326)NS
Cytogenetics, n (%)*.040
 Favorable20 (10.1%)2 (3.7%)
 Intermediate137 (68.8%)31 (57.4%)
 Adverse37 (18.6%)19 (35.2%)
 Missing5 (2.5%)2 (3.7%)
Secondary AML, n (%)46 (23.1%)23 (42.6%)0.004
No. of induction courses, n (%)NS
 1136 (68.3%)31 (57.4%)
 256 (28.1%)19 (35.2%)
 ≥37 (3.5%)4 (7.4%)
Consolidation therapy after initial induction, n (%)<.001
 No23 (11.6%)17 (31.5%)
 Yes176 (88.4%)37 (68.5%)
No. of consolidation courses.009
 192 (46.2%)19 (35.2%)
 ≥284 (42.2%)18 (33.3%)
No. of re-induction courses, n (%)NS
 141 (20.1%)16 (29.6%)
 28 (4.0%)2 (3.7%)
 ≥33 (1.5%)0 (0%)
Consolidation therapy after re-induction, n (%)NS
 No32 (16.1%)14 (25.9%)
 Yes20 (10.1%)4 (7.4%)
No. of consolidation coursesNS
 118 (9.1%)4 (7.4%)
 ≥22 (1.0%)0 (0%)
Median remission duration before HCT (range), d
 For CR1 patients127 (18-465)93 (16-383).015
 For CR2 patients59.5 (17-231)54 (17-203)NS
Peripheral blood counts before HCT.006
 ANC ≥1000/µL and platelets ≥100 000/µL176 (88.4%)40 (74.1%)
 ANC <1000/µL and/or platelets <100 000/µL22 (11.1%)14 (25.9%)
 Missing1 (0.5%)0 (0%)
Routine cytogenetics before HCT, n (%)<.001
 Normal karyotype183 (92.0%)39 (72.2%)
 Abnormal karyotype11 (5.5%)13 (24.1%)
 Missing/inadequate data5 (2.5%)2 (3.7%)
CR status, n (%)NS
 CR1147 (73.9%)36 (66.7%)
 CR252 (26.1%)18 (33.3%)
  • ANC, absolute neutrophil count; NS, not significant; WBC, white blood cell count.

  • * For the comparison MRDneg vs MRDpos.